Key Highlights
- Second-quarter Revenue was $12.6 million, down from $13.6 million a year earlier, with a net loss of $1.3 million.
- The Cyclo G6 glaucoma product line grew revenue 19%, driven by roughly 35% higher probe volume.
- Retina product sales declined due to commercial disruptions in the Middle East and reduced activity in the Chinese market.
- The company achieved positive Operating Cash Flow in the quarter and reaffirmed full-year revenue guidance of $51.0 million to $53.0 million.
IRIDEX Corporation (NASDAQ:IRIX), a maker of laser systems for treating eye disease, reported encouraging signs in its glaucoma Business and a return to positive operating cash flow, even as overall revenue softened. The question for investors is whether the higher-growth glaucoma Franchise and improving cost discipline can offset the weakness elsewhere in the business.
IRIDEX manufactures ophthalmic laser systems and related consumable probes, with product lines serving the glaucoma and retina treatment markets. Its glaucoma business, centered on its Cyclo G6 system and its recurring-revenue probes, has been a growth driver, while its retina business is more exposed to international market conditions. The mix of durable equipment and recurring consumables shapes its revenue profile.
Latest Developments
In its second-quarter 2026 results, IRIDEX reported revenue of $12.6 million, down from $13.6 million a year earlier, with a net loss of $1.3 million ($0.07 per share). The bright spot was glaucoma: its Cyclo G6 product line grew revenue 19%, driven by roughly 35% higher probe volume, reflecting growing adoption of its recurring-revenue consumables. Retina product sales declined, however, due to commercial disruptions in the Middle East and reduced activity in the Chinese market. Importantly, the company achieved positive operating cash flow in the quarter and held $4.7 million in cash, while reaffirming full-year revenue guidance of $51.0 million to $53.0 million and highlighting cost-reduction initiatives, including Manufacturing relocation.
Financial and Business Position
IRIDEX's results show a company with a promising, growing glaucoma franchise, particularly its recurring probe sales, offset by weakness in its retina business tied to specific international markets. The return to positive operating cash flow and the emphasis on cost reduction are encouraging signs of improving financial discipline, though the modest cash balance means execution matters. The growth in high-margin, recurring probe Volume is a positive indicator for the underlying business even as total revenue softened.
Stock-Market Context
The company carries a strong-buy analyst rating, and the pullback reflects the soft overall revenue despite the glaucoma strength. The case for improvement rests on the glaucoma franchise and recurring probe sales continuing to grow, the retina business recovering as international conditions normalize, and cost discipline improving profitability; the cautionary case is that overall revenue declined, and that a small company with a modest cash balance has limited room for missteps.
What Investors Should Watch
Investors may focus on continued growth in the Cyclo G6 glaucoma franchise and probe volumes, a recovery in the retina business as Middle East and China conditions evolve, the sustainability of positive operating cash flow, progress on cost-reduction initiatives, and performance against full-year guidance. Evidence that the glaucoma growth and cost discipline can offset the retina weakness and drive the company toward profitability would support the more constructive view.
IRIDEX presents the classic profile of a small medical-device company with a promising growth engine offset by pockets of weakness, and the key to evaluating it is separating the trajectory of its glaucoma franchise from the headwinds in its retina business. The Cyclo G6 glaucoma system and its associated single-use probes represent the more attractive part of the business, since the strong growth in probe volume reflects both increasing adoption of the system and the recurring, higher-margin revenue that consumables generate. The return to positive operating cash flow and the emphasis on cost reduction are encouraging signs that IRIDEX is improving its financial discipline and moving toward sustainable profitability.


_11_19_2026_08_23_11_186799.jpg)



Please wait processing your request...